A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Open accessPublished version of a preprint
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Background: Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients. Methods: The 24-week multicenter, randomized, double-blind, placebo parallel controlled clinical trial was conducted in AD in China between 24 October 2011 and 10 July 2013. The study included a 4-week screening/washout period, followed by a 24-week treatment period. Patients were randomized in a 1:1:1 ratio to receive GV-971 900 mg, 600 mg, or placebo capsule in treatment period, respectively. The primary outcome was cognitive improvement as assessed by changes in Alzheimer’s Disease Assessment Scale-cognitive subscale 12-item (ADAS-cog12) scores from baseline to week 24. The secondary efficacy outcomes included CIBIC-Plus, ADCS-ADL, and NPI at 24 weeks after treatment compared with baseline. A subgroup study was assessment of the change in cerebral glucose metabolism by fluorodeoxyglucose positron emission tomography measurements. Results: Comparing with the placebo group ( n = 83, change − 1.45), the ADAS-cog12 score change in the GV-971 600-mg group ( n = 76) was − 1.39 ( p = 0.89) and the GV-971 900-mg group ( n = 83) was − 2.58 ( p = 0.30). The treatment responders according to CIBIC-Plus assessment were significantly higher in the GV-971 900-mg group than the placebo group (92.77% vs. 79.52%, p < 0.05). The GV-971 900-mg subgroup showed a lower decline of cerebral metabolic rate for glucose than the placebo subgroup at the left precuneus, right posterior cingulate, bilateral hippocampus, and bilateral inferior orbital frontal at uncorrected p = 0.05. The respective rates of treatment-related AEs were 5.9%, 14.3%, and 3.5%. Conclusions: GV-971 was safe and well tolerated. GV-971 900 mg was chosen for phase III clinical study. Trial registration: ClinicalTrials.gov, NCT01453569 . Registered on October 18, 2011.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“New drugs, including sodium oligomannate (9, GV-971),54–56 aducanumab (1),57–59 lecanemab (2),60–62 and donanemab (10, currently under review for market approval),63 which aim to offer disease-modifying therapies that intervene in the progression of AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 37 · Cited by 103
Research works printed but not linked: 1
- Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33. · DOI · Paper page
Metadata
- Authors
- Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., Xiao, J., Li, H., Yan, C., Du, Y., Tang, M., He, Z., Chen, H., Li, W., Lin, H., Shi, S., Bi, J., Zhou, H., Cheng, Y., Gao, X., Guan, Y., Huang, Q., Chen, K., Xin, X., Ding, J., Geng, M., & Xiao, S.
- Affiliations
- Shanghai Jiao Tong University (CN)
- West China Hospital of Sichuan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Harbin Medical University (CN)
- Chinese People's Liberation Army (CN)
- Nanjing Brain Hospital (CN)
- Sun Yat-sen University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Baotou Central Hospital (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Guangzhou Psychiatric Hospital (CN)
- First Hospital of China Medical University (CN)
- Beijing Hospital (CN)
- Tang Du Hospital (CN)
- Southwest Hospital (CN)
- Second Hospital of Shandong University (CN)
- Daping Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- Hunan Provincial People's Hospital (CN)
- Fudan University (CN)
- Banner Alzheimer’s Institute (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Wang, Tao
- Geng, Meiyu
- Xiao, Shifu
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2020-09-14
- Volume
- 12
- Issue
- 1
- Pages
- 110-110
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC7489025
- OpenAlex
- W3085133919
- Cited by
- 103
- References
- 37
- Citations by year
- 2026: 16 · 2025: 12 · 2024: 15 · 2023: 22 · 2022: 23 · 2021: 14 · 2020: 1
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Major Scientific and Technological Special Project (2011ZX09101-003-01)
- National High Technology Research and Development Program of China (2006AA090501)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cognitive impairment, oligosaccharides, brain glucose metabolism, FDG-PET, precuneus, posterior cingulate cortex, hippocampus, treatment response, drug safety and tolerability, dose comparison, Chinese patients, CIBIC-Plus, NPI
- MeSH terms
- Alzheimer Disease, China, Cholinesterase Inhibitors, Double-Blind Method, Humans, Mannose, Oligosaccharides, Sodium, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. https://app.cochat.ai/papers/10.1186/s13195-020-00678-3
- The paper
- Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., Xiao, J., Li, H., Yan, C., Du, Y., Tang, M., He, Z., Chen, H., Li, W., Lin, H., . . . Xiao, S. (2020). A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00678-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.